Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 2c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.35), $0.02 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $18.93 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2021 revenue of $89-93 million, versus the consensus of $83.6 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance